Library · Muscle, bone & joint · Treatment of postmenopausal osteoporosis
Abaloparatide
BA058, ITM-058, Tymlos
Synthetic analog of parathyroid hormone-related protein, approved (Tymlos) for osteoporosis in postmenopausal women and high-risk men. Builds bone by boosting formation, raising bone density and lowering vertebral and non-vertebral fracture risk.
Research score 85/100. Reference only, not a dose.
Boxed warning: Osteosarcoma risk in animal studies
- Bone Health
- Healing
- Anti-inflammatory
- Collagen Production
- US status
- FDA Approved
- Approval
- FDA Approved
- Evidence
- FDA Approved for osteoporosis. 'Black box' warning for osteosarcoma removed in 2021.
- Research score
- 85 / 100
- Indication
- Osteoporosis
- Origin
- USA
- Source category
- Muscles & Joints
- Status group
- Approved / prescription
Mechanism
Selectively activates the PTH1 receptor, favoring RG over R0 signaling for an anabolic bias with less resorption. Promotes osteoblast differentiation and survival, raising cortical bone density and strength while shaping calcium handling.
Safety file
Can cause hypercalcemia, dizziness, and palpitations. Rodent-based osteosarcoma concern initially triggered a boxed warning, later removed or downgraded.
- Injection site reactions
- Dizziness
- Nausea
- Palpitations
- Headache
- Fatigue
- Hypercalciuria